Background
Post-tonsillectomy hemorrhage is one of the most important complications after tonsil surgery. Although most patients recover without major problems, bleeding after tonsillectomy can be frightening, may require urgent evaluation in the emergency department, and in some cases needs operative control in the operating room. The challenge for clinicians is that bleeding severity can vary widely, from minor oozing to brisk hemorrhage with airway risk and hemodynamic instability.
Tranexamic acid, commonly called TXA, is an antifibrinolytic medication that helps stabilize blood clots by slowing down clot breakdown. It is used in many areas of medicine, including trauma, surgery, obstetrics, and selected bleeding disorders. In post-tonsillectomy hemorrhage, TXA has gained attention as a non-operative option that may help reduce bleeding while clinicians determine whether the patient needs surgery.
Nebulized TXA is especially attractive in the emergency setting because it can be administered quickly and does not require swallowing pills or immediate IV access in every case. However, even when a treatment is supported by emerging evidence, turning that evidence into routine practice can be difficult. Staff turnover, limited familiarity with the medication, concerns about airway safety, and inconsistent ordering habits can all delay adoption.
This study examined whether implementing a clinical care guideline could improve adherence to a nebulized TXA protocol for post-tonsillectomy hemorrhage and whether that change would be associated with fewer operative interventions.
Study Objective
The purpose of the project was twofold. First, the authors wanted to standardize how patients with post-tonsillectomy bleeding were assessed and treated in the emergency department. Second, they wanted to determine whether consistent guideline-based use of nebulized TXA would influence the need for operative hemorrhage control.
In practical terms, the team asked whether a structured clinical care guideline could move TXA from an optional, inconsistently used therapy to a routine first-line adjunct for selected patients presenting with bleeding or clot after tonsillectomy.
How the Guideline Was Implemented
The team used Model for Improvement methodology to develop the clinical care guideline. This quality-improvement framework focuses on testing changes, measuring performance, and refining processes over time.
A treatment algorithm was created for patients who came to the emergency department with post-tonsillectomy bleeding. According to the protocol, patients with active bleeding or an obvious blood clot were to receive three nebulized TXA treatments. The order set was built into the workflow to make the process easier for clinicians and reduce variation in practice.
The protocol also included exclusion criteria. Patients with severe bleeding were not appropriate for this pathway, because they would likely need more urgent intervention. Patients without active bleeding or clot were also excluded, as were those unable to tolerate nebulized treatment or unable to protect their airway. These exclusions are important because post-tonsillectomy hemorrhage is not a one-size-fits-all condition; airway safety and bleeding severity must remain the first priorities.
By embedding the guideline into an order set, the team aimed to make correct treatment easier to deliver at the point of care, which is often the key to successful implementation in busy emergency settings.
Methods and Outcomes Measured
The investigators compared outcomes during the two years before and the two years after guideline implementation. They reviewed several measures, including:
1. Emergency department returns for post-tonsillectomy bleeding
2. Use of the TXA order set
3. Frequency of TXA administration in the emergency department
4. Returns to the operating room for hemorrhage control
5. Secondary returns to the emergency department
This before-and-after design does not prove cause and effect as strongly as a randomized trial, but it is a useful approach for evaluating real-world changes in clinical practice, especially when the goal is to improve care delivery across a hospital system.
Key Results
During the study periods, there were 2,805 tonsillectomies in the pre-implementation period and 5,382 tonsillectomies in the post-implementation period. The patient age distribution was similar between the two groups, which helps make the comparison more balanced.
Emergency department returns for bleeding occurred in 70 patients before implementation, representing 2.5%, and in 155 patients after implementation, representing 2.9%. This difference was not statistically significant, suggesting that the overall rate of post-tonsillectomy bleeding presentations did not meaningfully change between periods.
After the guideline was introduced, 126 patients met the inclusion criteria for TXA, accounting for 81.3% of the eligible group. That finding suggests the protocol identified a large number of patients who could reasonably receive nebulized TXA under the new pathway.
Importantly, the TXA order set was used in 95.7% of patients who received TXA in the emergency department. This is a strong signal of successful implementation. In quality-improvement work, high order-set utilization often reflects that clinicians recognize the protocol, trust it, and can access it easily during workflow.
The most clinically meaningful finding was a reduction in operative management. Before the intervention, 35 of 70 patients with emergency department bleeding returns underwent operative control of post-tonsillectomy hemorrhage, or 50%. After implementation, 42 of 155 patients returned to the operating room, or 27.1%. This difference was statistically significant, with p = 0.001. The reported adjusted risk reduction also favored the post-implementation period.
In simple terms, after the hospital introduced a standardized nebulized TXA pathway, fewer patients with post-tonsillectomy bleeding needed surgery to control the hemorrhage.
Clinical Interpretation
These results suggest that a structured guideline can help translate an emerging treatment into consistent bedside practice. Nebulized TXA appears to have been used rapidly and reliably after implementation, and that increased adherence was associated with fewer operative interventions.
There are several possible reasons for this effect. TXA may help stabilize clot formation in the tonsillar bed, reducing ongoing bleeding long enough for the hemorrhage to stop or become less severe. It may also serve as a useful temporizing measure, buying time for observation, resuscitation, ENT assessment, and decision-making. In some patients, this could mean the difference between going to the operating room and being managed conservatively.
At the same time, it is important not to overstate the findings. This was a retrospective quality-improvement study rather than a randomized controlled trial. The reduction in operative management may reflect protocol-driven early treatment, changing clinician behavior, differences in case mix, or other system-level factors. Even so, the magnitude of order-set adoption and the associated decline in operative returns make the findings clinically meaningful.
The study also reinforces an important principle in acute care medicine: introducing an evidence-based therapy is not enough. Hospitals often need clear algorithms, order sets, staff education, and follow-up measurement to ensure the therapy is actually used in the right patients.
Practical Implications for Emergency and ENT Teams
For emergency departments and otolaryngology services, this study supports the value of a standardized post-tonsillectomy bleeding pathway. A practical protocol can help clinicians quickly identify which patients may benefit from nebulized TXA and which patients need immediate escalation.
Potential advantages of a guideline-based approach include:
Better consistency in treatment decisions
Faster medication ordering and administration
Improved communication between ED and ENT teams
Potential reduction in OR utilization
More structured observation of patients with less severe bleeding
Nebulized TXA should be viewed as an adjunct, not a replacement, for thorough evaluation. Patients with severe bleeding, airway compromise, or unstable vital signs still require urgent specialist involvement and potentially operative control. Likewise, patients who are unable to protect their airway should not be treated with inhaled therapy alone.
This study also highlights the importance of order-set design. When an evidence-informed order is easy to find and built into the workflow, adoption improves dramatically. That lesson is widely applicable beyond TXA and post-tonsillectomy hemorrhage.
Limitations
Several limitations should be kept in mind when interpreting the results. First, the study design was observational and retrospective. That means the findings show association rather than definitive proof that TXA caused the reduction in OR returns.
Second, the article does not provide detailed information here about hemorrhage severity grading, timing from surgery to bleed, or other patient-level factors that may influence outcomes. These variables could affect the likelihood of surgery.
Third, practice patterns may have changed over time for reasons unrelated to the guideline, such as greater comfort with observation, differences in staffing, or broader institutional changes in ENT coverage.
Finally, the study focuses on implementation and operative outcomes, but it does not fully answer broader questions such as optimal dosing strategy, repeat dosing, long-term safety, or whether nebulized TXA should be used universally or only in selected cases. Those questions will require additional prospective research.
Conclusion
Implementation of a clinical care guideline for post-tonsillectomy hemorrhage was associated with rapid and high-level adoption of nebulized tranexamic acid in the emergency department. The intervention was also associated with fewer returns to the operating room for hemorrhage control.
For clinicians, the study supports the idea that well-designed protocols can make emerging therapies more usable in real-world care. For patients, it suggests that a standardized non-operative approach may help reduce the need for surgery in selected cases of post-tonsillectomy bleeding. Further prospective studies would be helpful to confirm the optimal role of nebulized TXA in this setting and to refine which patients benefit most.
Reference
Lavin J, Billings K, Smith A, Patel K, Corboy J, Hazkani I. Clinical Care Guideline Implementation of Nebulized Tranexamic Acid in Post-Tonsillectomy Hemorrhage. Laryngoscope. 2026 May 29. doi: 10.1002/lary.70641. Epub ahead of print. PMID: 42212485.